2 recruiting, 1 completed, 1 not yet recruiting. 4 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 4 | Recruiting 2, Completed 1, Not yet recruiting 1 |
| Phase 1 | 1 | Recruiting 1 |
Follow SCHIZOPHRENIA 1 (Disorder): new trials by email Literature Review of SCHIZOPHRENIA 1 (Disorder) trials Research Report on SCHIZOPHRENIA 1 (Disorder)
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Brain Imaging of DSP-2342 DSP-2342 - SCHIZOPHRENIA 1 (Disorder) | Phase 2 | Not yet recruiting | Johns Hopkins University | 20 | 2027-01-01 | 2026-09-30 |
| Confirmatory Trial of Gamma Neurofeedback to Improve Working Memory in Schizophrenia EEG Neurofeedback - SCHIZOPHRENIA 1 (Disorder), Schizoaffecitve Disorder | Phase 2 | Recruiting | University of California, San Diego | 104 | 2026-11-05 | 2026-11-10 |
| A PET/MRI Study of Cobenfy on Dopamine Transmission in Schizophrenia Xanomeline and trospium chloride (KarXT) - SCHIZOPHRENIA 1 (Disorder), Schizoaffecitve Disorder | Phase 1 / Phase 2 | Recruiting | New York State Psychiatric Institute | 12 | 2026-07-01 | 2026-07-14 |
| A Study Assessing the Efficacy and Safety of HS-10380 in Hospitalized Adults With Acute Schizophrenia HS-10380 Low Dose, HS-10380 Medium dose, HS-10380 High Dose - SCHIZOPHRENIA 1 (Disorder) | Phase 2 | Completed | Jiangsu Hansoh Pharmaceutical Co., Ltd. | 363 | 2024-05-23 | 2026-04-24 |
Schizophrenia (3)
Mental Disorders (3) · Schizophrenia Spectrum and Other Psychotic Disorders (3)
Aripiprazole (1) · trospium chloride (1) · xanomeline (1)
Jiangsu Hansoh Pharmaceutical Co., Ltd. (1) · Johns Hopkins University (1) · New York State Psychiatric Institute (1) · University of California, San Diego (1)
United States (3) · China (1)
Akira Sawa, MD (1) · Fiza Singh, MD (1) · Joshua T Kantrowitz, MD (1) · Ragy Girgis, MD (1)